Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is aimed at regaining compliance with Nasdaq listing requirements.
The split-adjusted trading of common stock is set to begin on August 18, 2025.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split to maintain Nasdaq listing compliance.
Shareholder Impact
The reverse split will reduce outstanding common stock from 4.77 million shares to approximately 1.59 million shares.
CEO Statement
Interim CEO Richard Paolone highlighted the split as a strategic move to enhance shareholder value and market visibility.
- The reverse stock split aims to strengthen the company's position on the Nasdaq Capital Market.
- Entero Therapeutics expects the split to positively impact shareholder value and market perception.
The reverse stock split reflects Entero Therapeutics' commitment to regulatory compliance and market competitiveness.